Lipella Pharmaceuticals Inc. (LIPO)

NASDAQ: LIPO · IEX Real-Time Price · USD
0.680
+0.011 (1.63%)
At close: Jun 14, 2024, 3:26 PM
0.651
-0.029 (-4.22%)
After-hours: Jun 14, 2024, 6:55 PM EDT
1.63%
Market Cap 5.17M
Revenue (ttm) 477,449
Net Income (ttm) -4.74M
Shares Out 7.61M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,313
Open 0.650
Previous Close 0.669
Day's Range 0.650 - 0.680
52-Week Range 0.601 - 2.710
Beta n/a
Analysts Strong Buy
Price Target 2.00 (+194.16%)
Earnings Date Aug 12, 2024

About LIPO

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (G... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 20, 2022
Employees 5
Stock Exchange NASDAQ
Ticker Symbol LIPO
Full Company Profile

Financial Performance

In 2023, LIPO's revenue was $449,617, an increase of 144.15% compared to the previous year's $184,156. Losses were -$4.62 million, 77.8% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for LIPO stock is "Strong Buy" and the 12-month stock price forecast is $2.0.

Price Target
$2.0
(194.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

Lipella Pharmaceuticals' LP-310 clinical stage asset is formulated for delivering active agents to the oral cavity for diseases of the mouth including oral lichen planus and oral graft-versus-host dis...

7 months ago - PRNewsWire

Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

PITTSBURGH , Oct. 25, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases w...

8 months ago - PRNewsWire

Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

PITTSBURGH , Oct. 24, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases w...

8 months ago - PRNewsWire

Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment

Shares of Lipella Pharmaceuticals Inc. LIPO, +51.55% rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company's investigational new drug application for it...

8 months ago - Market Watch

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus

LP-310 is an oral formulation of Lipella's lead asset LP-10. PITTSBURGH , Oct. 20, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinic...

8 months ago - PRNewsWire

Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology

Article highlights results from successful Phase 2a clinical trial for lead candidate, LP-10 Lipella expects to initiate Phase 2b clinical trial in LP-10 in early 2024 PITTSBURGH, Pa. , Sept. 21, 2023...

9 months ago - PRNewsWire

Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

Successful top line results from Phase 2a clinical trial for lead candidate LP-10 Oral Health Scientific Advisory Board established to focus on development of LP-310 for oral lichen planus Late-breaki...

1 year ago - PRNewsWire

Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting

Presentation Focused on Positive Results from Recent Phase 2a Study PITTSBURGH , May 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a c...

1 year ago - PRNewsWire

Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

PITTSBURGH, April 17, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant...

1 year ago - PRNewsWire

Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent

Lipella awarded $1.35m grant in 2022 for development of intravesical contrast-enhanced magnetic resonance imaging (ICE-MRI) technology. PITTSBURGH , April 5, 2023 /PRNewswire/ -- Lipella Pharmaceutica...

1 year ago - PRNewsWire

Lipella Provides Business Update and Reports 2022 Financial Results

Company Successfully Completes Phase 2a Clinical Trial Fourth Quarter or Full Year Highlights • Appointed Douglas Johnston as CFO in November 2022 • Successfully completed Initial Public Offering, att...

1 year ago - PRNewsWire

Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association

PITTSBURGH, March 16, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company") today announced the successful completion of a Phase 2A clinical trial...

1 year ago - PRNewsWire

Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board

Five-member Board will initially focus on the development of LP-310 PITTSBURGH , March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stag...

1 year ago - PRNewsWire

Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10

Results to be Presented at BIOTECH SHOWCASETM 2023 on Wednesday, January 11 th at 2:00pm PST PITTSBURGH , Jan. 11, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, ...

1 year ago - PRNewsWire

Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco

PITTSBURGH, Jan. 9, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by...

1 year ago - PRNewsWire